Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avai Bio (AVAI) EBT (2018 - 2025)

Avai Bio's EBT history spans 6 years, with the latest figure at -$4.0 million for Q1 2024.

  • On a quarterly basis, EBT fell 268.83% to -$4.0 million in Q1 2024 year-over-year; TTM through Mar 2024 was -$5.8 million, a 581.5% decrease, with the full-year FY2025 number at -$1.1 million, up 46.34% from a year prior.
  • EBT hit -$4.0 million in Q1 2024 for Avai Bio, down from -$1.0 million in the prior quarter.
  • Over the last five years, EBT for AVAI hit a ceiling of $417163.0 in Q4 2020 and a floor of -$4.0 million in Q1 2024.
  • Historically, EBT has averaged -$559193.0 across 4 years, with a median of -$225041.5 in 2020.
  • The widest YoY moves for EBT: up 4203.92% in 2020, down 1770.01% in 2020.
  • Tracing AVAI's EBT over 4 years: stood at $417163.0 in 2020, then plummeted by 73.52% to $110471.0 in 2022, then plummeted by 1017.8% to -$1.0 million in 2023, then tumbled by 289.93% to -$4.0 million in 2024.
  • Business Quant data shows EBT for AVAI at -$4.0 million in Q1 2024, -$1.0 million in Q4 2023, and -$399621.0 in Q3 2023.